Companies › Oneness Biotech
3 active drug programs in 4 registered trials: 3 Phase 2, 1 Phase 1; Metabolic and endocrine, Immunology; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| FB825 | – | Phase 2 | Atopic Dermatitis; Allergic Asthma | May 2027 |
| Xianglei Tangzu Gao Herbal preparation containing extracts of Plectranthus amboinicus and Centella asiatica | – | Phase 2 | Diabetic Foot Ulcer | – |
| SNS851 siRNA treatment targeting metabolic diseases | – | Phase 1 | Metabolic Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06531512 | Xianglei Tangzu Gao | Phase 2 | Diabetic Foot Ulcer | Metabolic and endocrine | May 2026 |
| NCT07417124 | SNS851 | Phase 1 | Metabolic Disease | Metabolic and endocrine | Oct 2026 |
| NCT06397911 | FB825 | Phase 2 | Atopic Dermatitis | Immunology | May 2027 |
| NCT05008965 | FB825 | Phase 2 | Allergic Asthma | Immunology | Dec 2027 |
No annotated target.
–
Rare Thyroid Therapeutics International Eddingpharm (Zhuhai) Ribotek Biopharmaceuticals (Shandong) Amorphical Alveus Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.